IntraBiotics Pharmaceuticals Inc., of Mountain View, Calif., promoted Henry Fuchs to president and chief operating officer.
Leerink Swann & Co., of Boston, added David Cronin as vice president of sales trading, Daniel Linehan as senior vice president of Nasdaq trading, and Charlie O’Connor as assistant trader.
Lipocine Inc., of Salt Lake City, named Srinivasan Venkateshwaran vice president of research and development and Steven Krill vice president of technology development.
MDS Proteomics, of Toronto, a subsidiary of MDS Inc., named Anil Amlani chief financial officer.
Memorial Sloan-Kettering Cancer Center, of New York, appointed Robert Wittes physician-in-chief of Memorial Hospital and Thomas Kelly chairman of the Sloan-Kettering Institute.
Metabasis Therapeutics Inc., of San Diego, formed its scientific advisory board, consisting of Montgomery Bissell, Alan Cherrington, Anna Diehl, Jules Dienstag, Heinz Gschwend, David Herzig, Gerald Shulman, Alan Venook and David Waxman.
Nautilus Biotech, of Paris, appointed Peter Horn vice president for business development.
NeoTherapeutics Inc., of Irvine, Calif., appointed Dilip Mehta to its scientific advisory board.
Neurogenetics Inc., of La Jolla, Calif., appointed Kumar Srinivasan director of corporate development.
Panacos Pharmaceuticals Inc., of Gaithersburg, Md., appointed Donald Zelm chief financial officer.
PanTherix Ltd., of Glasgow, UK, appointed Alan Clark nonexecutive chairman and Robin Cooper as a board member.
Phage Therapeutics International Inc., of Bothell, Wash., appointed Randal Goffe to its board.
ProMetic Life Sciences Inc., of Montreal, appointed Chris Penney director of research and development, therapeutic programs; Boulos Zacharie, director of chemistry; and Lyne Gagnon, director of biology.
Samaritan Pharmaceuticals Inc., of Las Vegas, recruited Jing XU for its research team.
Sangui BioTech International Inc., of Santa Ana, Calif., elected Edgar Fritschi to the supervisory boards of its subsidiaries, SanguiBioTech AG and GlukoMediTech AG, and also to the board of directors of Sangui Biotech International Inc. and Sangui BioTech Inc.
Senesco Technologies Inc., of New Brunswick, N.J., elected Bruce Galton to its board.